Author

R. Del Río Villegas

h-index 8 View on Semantic Scholar

We have 2 of 42 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials.

BACKGROUND Narcolepsy type 1 is characterized by excessive daytime sleepiness, cataplexy, disrupted sleep, sleep paralysis, and hypnagogic or hypnopompic hallucinations. Oveporexton (TAK-861), an oral orexin receptor 2-selective agonist, reduced symptoms of narcolepsy type 1 in a previous phase 2 trial. METHODS We co...

Y. Dauvilliers, Emmanuel Mignot, Jakub Antczak et al. · New England Journal of Medic... · 1 citation

Aug 2026

Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

BACKGROUND The clinical potential of orexin 2 receptor (OX2R) agonism for improving measures of wakefulness and cataplexy in patients with narcolepsy type 1 has been described in a phase 2 study. Here, we aimed to evaluate the safety, tolerability, and efficacy of alixorexton, another oral OX2R agonist, in narcolepsy t...

G. Plazzi, Ronald R. Grunstein, Emmanuel Mignot et al. · Lancet Neurology · 1 citation